ALBUTEROL SULFATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for ALBUTEROL SULFATE (ALBUTEROL SULFATE).
Beta-2 adrenergic receptor agonist resulting in bronchodilation via increased cyclic AMP synthesis and smooth muscle relaxation.
| Metabolism | Extensively metabolized via catechol-O-methyltransferase (COMT) and conjugation; hepatic metabolism also occurs. |
| Excretion | Approximately 72% of an inhaled dose is recovered in urine as unchanged drug and metabolites (28% as sulfate conjugate) within 24 hours; fecal elimination accounts for less than 10%. |
| Half-life | Terminal elimination half-life is 3.8–6 hours after inhalation; in patients with hepatic impairment, half-life may be prolonged up to 8 hours. |
| Protein binding | Approximately 10% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Mean Vd is 1.6–2.0 L/kg after IV administration, indicating extensive distribution into tissues. |
| Bioavailability | Inhalation: 10–20% of the dose reaches the lungs systemically; oral: approximately 50% (first-pass metabolism; active metabolite formed). |
| Onset of Action | Inhalation: 5–15 minutes; oral immediate-release: 30–60 minutes. |
| Duration of Action | Inhalation: 4–6 hours (shorter in severe asthma or with tolerance); oral: 4–6 hours (immediate-release); extended-release oral: up to 12 hours. |
| Molecular Weight | 239.31 |
2 puffs (90 mcg/puff) via metered-dose inhaler q4-6h as needed; or 2.5 mg via nebulization q4-6h as needed
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for any degree of renal impairment |
| Liver impairment | No dose adjustment required for any Child-Pugh class (A, B, or C) |
| Pediatric use | Children 2-12 years: 1-2 puffs (90 mcg/puff) via MDI q4-6h as needed; or 0.15 mg/kg (min 1.25 mg, max 2.5 mg) via nebulization q4-6h as needed |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to increased sensitivity to beta-adrenergic effects; monitor for tachycardia and tremor |
| 1st trimester | Albuterol is generally avoided in the first trimester unless clearly needed, as data are limited. However, no major teratogenic effects have been consistently demonstrated in animal studies at supratherapeutic doses. |
| 2nd trimester | Use cautiously; albuterol can be used as a bronchodilator for asthma exacerbations, but may cause transient fetal tachycardia and hyperglycemia. Benefits usually outweigh risks. |
| 3rd trimester | Use with caution; albuterol may delay labor (tocolysis) and cause maternal and fetal tachycardia, hyperglycemia, hypokalemia. Avoid near term if possible. |
Clinical note
Comprehensive clinical and safety monograph for ALBUTEROL SULFATE (ALBUTEROL SULFATE).
| Placental transfer | Albuterol crosses the placenta via passive diffusion; umbilical cord concentrations are 50-100% of maternal plasma levels. Transfer is rapid and concentration-dependent. |
| Breastfeeding | Albuterol is excreted into breast milk in small amounts (estimated relative infant dose <1% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Use with caution in preterm infants or those with pre-existing tachycardia. |
| Lactation Rating | L2 (Safe) |
| Teratogenic Risk | Pregnancy category C. Inhaled albuterol is not associated with major congenital malformations in first trimester. Second and third trimester use may cause fetal tachycardia, hyperglycemia, and transient neonatal hypoglycemia. High-dose intravenous or oral use increases risk of uterine relaxation, maternal tachycardia, and potential placental hypoperfusion. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, serum potassium, and glucose levels. In pregnancy, assess fetal heart rate and uterine activity during acute use. For chronic use, serial growth ultrasound is recommended due to potential fetal growth restriction from maternal disease. |
| Fertility Effects | No direct impairment of fertility in animal studies. Severe asthma may indirectly reduce fertility due to hypoxia and systemic inflammation. Beta-agonists may not significantly affect reproductive function. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to albuterol or any componentPreterm labor (as tocolytic in acute setting) — use is contraindicated for prolonged tocolysis due to risk of maternal pulmonary edema and fetal acidosisConcurrent use of non-selective beta-blockers (e.g., propranolol) — potential for severe bronchospasm
| Precautions | Paradoxical bronchospasm may occur with excessive use, Cardiovascular effects (tachycardia, arrhythmia) especially with concurrent beta-blocker use, Hypokalemia risk with high doses, Use caution in patients with hyperthyroidism, diabetes, or seizure disorders |
| Food/Dietary | No significant food interactions reported with albuterol sulfate. However, caffeine-containing foods or beverages (e.g., coffee, tea, cola) may theoretically potentiate stimulant effects such as increased heart rate or nervousness, though clinical significance is minimal. Patients should maintain normal dietary habits unless directed otherwise by their healthcare provider. |
| Clinical Pearls | Albuterol sulfate is a short-acting beta-2 agonist (SABA) used for acute bronchospasm relief. Onset of action is within 5-15 minutes by inhalation. Monitor for paradoxical bronchospasm, which may require discontinuation. Not indicated for maintenance therapy in asthma without concomitant inhaled corticosteroid. Can cause hypokalemia, especially at high doses; monitor potassium in at-risk patients. Use with caution in patients with cardiovascular disease, as beta-agonists can increase heart rate and blood pressure. Albuterol is pregnancy category C; use only if clearly needed. Nebulized albuterol is preferred for acute severe asthma exacerbations. Inhaled albuterol may be combined with ipratropium for acute exacerbations. |
| Patient Advice | Use albuterol exactly as prescribed; it is for quick relief of wheezing and shortness of breath, not for daily prevention unless directed. · Rinse your mouth with water after using the inhaler to prevent dry mouth and throat irritation. · Shake the inhaler well before each use and prime it if not used for more than 2 weeks. · If you need more than 2 puffs twice a week for symptom relief, consult your doctor as your asthma may not be well-controlled. · Seek emergency medical help if you have worsening symptoms, chest tightness, or if the medication does not provide relief. · Avoid spraying albuterol into your eyes; if accidental contact occurs, rinse with water for several minutes. · Inform your doctor if you are pregnant, breastfeeding, or have heart problems, high blood pressure, seizures, or diabetes. · Store the inhaler at room temperature away from heat and open flame; do not puncture. |
Loading safety data…